Acute kidney injury stage 1a increases mortality of patients with cirrhosis: a prospective multicenter cohort study
- PMID: 40014296
- DOI: 10.1007/s12072-025-10790-x
Acute kidney injury stage 1a increases mortality of patients with cirrhosis: a prospective multicenter cohort study
Abstract
Background and aims: Acute kidney injury is a severe complication of cirrhosis. However, the impact of mild decreases in renal function is controversial. This study aims to evaluate the prognosis of the different stages of acute kidney injury in cirrhosis.
Methods: This is a multicenter prospective cohort study of patients hospitalized for acute decompensation of cirrhosis, with serum creatinine values measured at least twice. Primary outcome was mortality (in-hospital, 30 days, 90 days and 12 months).
Results: Nine hundred twenty-eight patients were included in the study. Acute kidney injury was diagnosed in 505 patients (stages 1a-21.6%, 1b-27.5%, 2-28.1%, 3-22.8%). Mortality rates of patients with acute kidney injury stage 1a were significantly higher than those of individuals without acute kidney injury (in-hospital-19.3% vs 4.7%; 30-day-21.8% vs 6.7%; 90-day-35.2% vs 17.5%; 12-month-54.1% vs 37.1%; p < 0.05 for all comparisons). Mortality rates were even higher for acute kidney injury stages 1b, 2 and 3. Survival analysis demonstrated that patients without acute kidney injury performed significantly better than those with any stage of acute kidney injury (p < 0.01). Acute kidney injury stages 1a, 1b, 2 and 3 were independently associated with survival in the multivariate analysis (p < 0.01).
Conclusions: Patients hospitalized for acute decompensation of cirrhosis who develop acute kidney injury have significantly higher mortality rates than those who do not develop this complication. This is true even for the mildest stages of acute kidney injury (stage 1a) and remains so at different time-points, supporting recommendations for earlier treatments.
Keywords: Chronic liver disease; Hepatorenal syndrome; Long-term; Multivariate analysis; Phenotype; Renal function; Serum creatinine; Staging; Survival; Treatment response.
© 2025. Asian Pacific Association for the Study of the Liver.
Conflict of interest statement
Declarations. Conflict of interest: Ângelo Z. Mattos, Caroline Machado Rotta Dornelles, Leonardo de Lucca Schiavon, Liliana Sampaio Costa Mendes, Roberto José de Carvalho Filho, Liana Codes, Alberto Queiroz Farias, Mário Reis Álvares-da-Silva, Carlos Terra, Gustavo Pereira, Muriel Manica, Helena Marcon Bischoff, Janaína Luz Narciso Schiavon, Silas Gustavo Barboza Romeres, Jéssica Bastos Garcia, Paulo Lisboa Bittencourt, Rafael Oliveira Ximenes, Raul Salinas Arrojo, Angelo A. Mattos and Alliance of Brazilian Centers for Cirrhosis Care – the ABC Group have no relevant financial or non-financial interests to disclose. Ethical approval: The study was approved by the institutional review board of each participating center. Informed consent: All procedures followed were in accordance with the ethical standards of the responsible committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008. Informed consent was obtained from all patients or their surrogates for being included in the study.
References
-
- European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69:406–460 - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical